Brief: Axcella Reports First Quarter Financial Results
May 4 (Reuters) - Axcella Health Inc AXLA.O :
* AXCELLA REPORTS FIRST QUARTER FINANCIAL RESULTS AND
PROVIDES
BUSINESS UPDATE
* AXCELLA HEALTH INC - LONG COVID PHASE 2B/3 CLINICAL TRIAL
MAY
PROCEED UNDER U.S. INVESTIGATIONAL NEW DRUG APPLICATION
* AXCELLA HEALTH INC - AS OF MARCH 31, 2023, CASH AND CASH
EQUIVALENTS TOTALED $12.5 MILLION
* AXCELLA HEALTH INC - QTRLY NET LOSS PER DILUTED SHARE
$0.05
Source text for Eikon: ID:nBwVYymwa
Further company coverage: AXLA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Axcella Health
See all newsAxcella Health Inc expected to post a loss of $1.25 a share - Earnings Preview
Brief: Axcella Health Inc- On Oct 4, Co Received Notice From Nasdaq That Co Had Regained Compliance With Nasdaq
Brief: Axcella Announces Reverse Stock Split Effective September 19, 2023
U.S. STOCKS ON THE MOVE-PDD Holdings, Catalent, Best Buy
Brief: Axcella Granted Patent For Long Covid Fatigue Treatment